Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Golimumab Plus UVB-311nm in Psoriasis

This study has been terminated.
(Difficulties in recruiting patients;)
Information provided by (Responsible Party):
Peter Wolf, MD, Medical University of Graz Identifier:
First received: March 15, 2010
Last updated: June 23, 2014
Last verified: June 2014
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: October 2010
  Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)